68ga-aazta-ni-093

**Description:** 68ga-aazta-ni-093 is a novel radiotracer designed for positron emission tomography/computed tomography (PET/CT) imaging. It incorporates a hypoxia-sensitive nitroimidazole (NI) moiety and a prostate-specific membrane antigen (PSMA)-targeting group. This dual-targeting approach allows the tracer to accumulate selectively in hypoxic tumor cells that overexpress PSMA, which is common in prostate cancer and other solid tumors. The agent is intended for diagnostic imaging of prostate cancer and potentially other PSMA-expressing malignancies[1][3][6]. **Mechanism of Action:** The drug combines two targeting strategies: 1. **PSMA Targeting:** Binds to prostate-specific membrane antigen overexpressed on prostatic adenocarcinoma cells. 2. **Hypoxia Targeting:** The nitroimidazole moiety becomes trapped inside hypoxic cells due to chemical reduction under low oxygen conditions. This results in enhanced tumor uptake and retention compared to normoxic tissues[5][8].

Other names

68Ga-AAZTA-NI-PSMA-093[68Ga]Ga-Azta-Ni-Psma-093